The authors reply: In the large survey that led to the development of the International Staging System (ISS) in multiple myeloma, anemia was associated with a shorter survival time in univariate analysis but was not one of the most powerful prognostic indicators in multivariate analysis. 1 Anemia is currently considered part of the related organ and tissue impairment that separates smoldering myeloma from symptomatic myeloma. 2 In the ISS, the cutoff values for β 2 -microglobulin are 3.5 mg per liter for stage II multiple myeloma and 5.5 mg per liter for stage III multiple myeloma. According to this widely accepted classification, our patient had stage I disease. The deletion of chromosome 13 is associated with a poorer outcome when it is detected with the use of conventional cytogenetic analysis. 3 The references cited by Louw et al. with respect to fluorescence in situ hybridization (FISH) are old. We now know that the negative prognostic effect of the chromosome 13 deletion, as detected with the use of FISH, is actually related to other associated abnormalities, such as a t(4;14) translocation and a partial deletion on chromosome 17p. Patients who have only a chromosome 13 deletion have the same prognosis as patients who do not have this abnormality. 4 The patient in our vignette had only a chromosome 13 deletion, as detected with the use of FISH, with no other adverse prognostic factors. 
Medical End-of-Life Practices under the Euthanasia Law in Belgium
To the Editor: The legalization of physicianassisted death for terminally ill patients is a controversial medical and societal issue. 1 In Belgium, where euthanasia was legalized in 2002, we conducted a follow-up study in 2007 to two largescale nationwide surveys on medical end-of-life practices that had been conducted in 1998 2 and 2001. 3 This follow-up study enabled us to investigate differences in the frequency and characteristics of these practices before and after the enactment of the law. We conducted the study with the use of data from death certificates in the Flemish-speaking part of Belgium, which has approximately 6 million inhabitants. A random sample of 6927 cases was drawn from all deaths that occurred from June 1, 2007, through November 30, 2007. The certifying physician in the case of each death was sent a five-page questionnaire about medical end-of-life practices that, according to their assessment, had a possible or certain life-shortening effect. The study protocol is described extensively elsewhere. 4 The response rate was 58.4% (Table 1 ). In 2007, 1.9% of all deaths in Flanders were the result of euthanasia (ending of life at the patient's explicit request), a rate that was higher than that in 1998 (1.1%) and 2001 (0.3%). In 1.8% of all In the case of 14.5% of all deaths, physicians reported using continuous and deep sedation until death, a rate that was substantially higher than that in 2001 (8.2%). Across the three studies, we found no shift in the characteristics of patients whose death was the result of euthanasia (mostly younger patients, patients with cancer, or patients dying at home) or in the characteristics of patients in whom lethal drugs were used without the patient's explicit request (mostly older, incompetent patients; patients with cardiovascular diseases or cancer; or patients dying in hospitals). The rate at which medical end-of-life practices were discussed between the physician and competent patients and their relatives was substantially higher in 2007 than in 1998 and was similar to the rate in 2001. The 2007 survey had the same robust design and asked the same key questions as did the previous surveys. We found that the enactment of the Belgian euthanasia law was followed by an increase in all types of medical end-of-life practices, with the exception of the use of lethal drugs without the patient's explicit request. No shift toward the use of life-ending drugs in vulnerable patient groups was observed. However, Continuous deep sedation -% (95% CI) § NA 8.2 (7.2-9.4) ¶ 14.5 (13.1-15.9) * All percentages were adjusted for stratification (according to the underlying cause of death as indicated on the death certificate and the estimated corresponding likelihood of an end-of-life decision's having been made) and for characteristics of deaths (age and sex of the patient and place and cause of death). CI denotes confidence interval, and NA not available. † From an analysis of nonresponse after the study, we found that a response was impossible in the case of 725 deaths (e.g., because the physician was deceased or had never received the questionnaire). Thus, of the 6927 deaths in the initial sample, 6202 were included in the final study sample. No such analysis of nonresponse was conducted in 1998 or 2001. ‡ The physician indicated in the questionnaire that the patient had died suddenly and unexpectedly, which precluded any medical end-of-life practice that hastened death. § The 95% CIs were calculated by means of a complex-samples procedure (Monte Carlo simulation) to account for the stratification. ¶ There was a significant difference in the frequency of this practice as compared with the frequency of the same practice in 2007 (P<0.05, with the use of the Fisher's exact test [Monte Carlo]). ‖ Ending of life at patient's explicit request (euthanasia) refers to the administration of lethal drugs with the explicit intention of ending the patient's life, at his or her explicit request; physician-assisted suicide refers to the prescription or supply of lethal drugs with the intention of enabling the patient to end his or her life; ending of life without patient's explicit request refers to the administration of lethal drugs with the explicit intention of ending the patient's life, without his or her explicit request.
